Schrödinger: Conviction Remains High, Q4 Report And Guidance Will Be CriticalSeeking Alpha • 01/06/22
Schrödinger Reports Preclinical Data Supporting Advancement Of Its MALT1 Inhibitor Program At American Society Of Hematology 2021 Annual MeetingBusiness Wire • 12/11/21
Schrödinger, Inc.'s (SDGR) CEO Ramy Farid on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/11/21
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/11/21
Schrödinger Reports Third Quarter 2021 Financial Results and Provides Company UpdateBusiness Wire • 11/10/21
Schrödinger to Present New Preclinical Data From Its MALT1 Inhibitor Program at ASH 2021 Annual MeetingBusiness Wire • 11/04/21
Earnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to DeclineZacks Investment Research • 11/03/21
Schrödinger to Host Conference Call to Discuss Third Quarter 2021 Financial ResultsBusiness Wire • 10/29/21
Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor AgonistsBusiness Wire • 10/18/21
MD Anderson and Schrödinger Announce Strategic Research Collaboration to Accelerate Development of WEE1 ProgramBusiness Wire • 10/07/21